Compare RLMD & MZYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLMD | MZYX |
|---|---|---|
| Founded | 2004 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.8M | 375.0M |
| IPO Year | 2012 | 2026 |
| Metric | RLMD | MZYX |
|---|---|---|
| Price | $3.25 | $9.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 39.6K |
| Earning Date | 11-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $2.15 | $9.90 |
| 52 Week High | $8.00 | $10.10 |
| Indicator | RLMD | MZYX |
|---|---|---|
| Relative Strength Index (RSI) | 38.09 | 51.96 |
| Support Level | $3.13 | $9.91 |
| Resistance Level | $3.55 | $10.03 |
| Average True Range (ATR) | 0.20 | 0.01 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 32.28 | 66.67 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
MOZAYYX Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.